myGeneticRisk myGeneticRisk is the preventive genetic test that allows a person to find out their hereditary risk of cardiovascular disease and cancer, the most common diseases worldwide. Knowing a person’s predisposition to these diseases allows the specialist to establish medical management strategies to prevent them or detect them at an early stage when it is possible to treat them effectively. From the enormous amount of information contained in your DNA, we will study 162 genes related to diseases of clinical relevance for which it is possible to take action in order to prevent them or detect them early. The test analyses the genes related to cardiovascular diseases and to the risk of cancer, in addition to a full analysis of other diseases whose study has been recommended by the ACMG (American College of Medical Genetics and Genomics). Genetic test for the prevention of cardiovascular disease and cancer Who is it aimed at? Any healthy person who is proactive in looking after their health. Amateur and professional athletes who want to find out about their risk of cardiovascular disease in order to play sport more safely. People who want to find out about their risk of hereditary cancer. myGeneticRisk analyses the risk of common genetic diseases It enables preventive medicine strategies to be established.It analyses the genetic risk of developing common hereditary diseases.It analyses 162 genes, including the genes recommended by the ACMG (American College of Medical Genetics and Genomics) related to actionable diseases.It is a one-time process and, in the event that a variant is detected, it enables genetically-tailored prevention strategies to be established.If a variant is detected, it enables family members that may be at risk to be studied in order for them to also benefit from prevention strategies.It includes a genetic counselling appointment before and after the test to assess its suitability, explain the results and establish the next steps. myGeneticRisk includes Whole exome sequencing and interpretation of 162 selected genes. Storage of the sequencing data that enables data to be re-analysed at a later date.Option to expand the study to other genes of interest for the specialist.Access to a diagnostic interpretation service of the Exome.Counselling offered by geneticists, both for the patient and the specialist, upon request.In the event of the reclassification of previously reported variants, the specialist will be updated regarding the information when it has a clinical impact.Results report available in 8 weeks. Are you interesting in offering myCardio from Veritas? Contact us and find out how we can work together. CONTACT DOWNLOAD MEDICAL BROCHURE Are you interested in myCardio but you do not have a doctor that provides the service? Our medical professionals can help you. Please click on the below button to learn more. PURCHASE TEST DOWNLOAD PATIENT BROCHURE myGeneticRisk Advantages Genetic diagnosis has significantly reduced death from hereditary heart disease and cancer. from hereditary heart disease and cancer. Common diseases: The diseases studied are the most common among the population and a significant percentage have a genetic origin. Prevention: The test result enables medical management to be tailored in accordance with the results and prevention strategies to be put in place, if required. Up-to-date results: The team of geneticists analyse the genetic data and ensure that the results are issued based on the most up-to-date scientific knowledge. Detailed report: Report with detailed medical content. AGenetic counselling: Differentiated expert genetic counselling service in different medical areas. Service for specialists and patients. Continued updating: Updating of the classification of variants with clinical importance. Veritas offers access to information of interest that may be incorporated in the future. Advice to the specialist Veritas provides a differential service by providing advice to the specialist for the interpretation of his patient’s results, whenever needed. Why is it important? 5-20% Between 5 -20% of cancer cases are of hereditary origin, the percentage varies according to the type of cancer. 30% Approximately 20% of sudden deaths are due to genetic abnormalities related to the structure of the heart muscle or heart rate. 2,5% Approximately 2.5% of people present a variant in the genes recommended by the ACMG. I want to request myGeneticRisk, what do I need to do? 1. Purchase your kit. In the Veritas kit, you will find everything you need to take a saliva sample. 2. Have a pre-test Genetic Counselling Appointment. We will contact you to arrange an online or face-to-face genetic counselling appointment. During the appointment, a geneticist will explain the objective and scope of the test to you. 3. Receive your kit. Receive your sample collection kit at the address you provide. To take the sample, you must not have had anything to eat or drink for 30 minutes beforehand. 4. Request collection of the sample. A courier will collect the kit with your sample at the address you provide. 5. We analyse your sample. We extract and sequence the DNA. Then, we interpret the genomic data based on the most up-to-date clinical information to provide clear and useful information. 6. We prepare a detailed report. Your results report will be ready within 8 weeks, and we will give this to you at the post-test genetic counselling appointment. 7. Post-test Genetic Counselling Appointment. During the appointment, the geneticist will explain the results and the impact they have on your health, and they will determine the next steps with you. If you want to be proactive in looking after your health and know about your risk of hereditary diseases related to cancer and cardio, myGeneticRisk is the genetic test you need. Possible results Pathogenic and probably pathogenic variants classified based on American College of Medical Genetics and Genomics (ACMG) guidelines (PMID: 25741868) are included in the report. Why Veritas? Veritas is The Genome Company, leader in whole genome and exome sequencing, with a wealth of experience in the analysis and interpretation of variants in healthy patients and those with diseases.Veritas’ tests have been developed by an expert medical team, including members of the Personal Genome Project from the Faculty of Medicine at the University of Harvard. Sequencing of the whole exome with an average 100x coverage with more than 99% covered to ≥20x in the genes of interest.
